Molnár Tamás
Szegedi Tudományegyetem, Altalános Orvostudományi Kar, I. Belgyógyászati Klinika, Szeged.
Orv Hetil. 2009 Sep 20;150(38):1773-9. doi: 10.1556/OH.2009.28689.
The introduction of TNF-alpha blocking therapy has produced a dramatic change in the treatment of therapy resistant patients with inflammatory bowel disease. Both infliximab and adalimumab are effective in moderately severe and severe Crohn's disease. Besides, infliximab is potent in the remission and its sustaining in ulcerative colitis. However, among therapy resistant individuals, 20-30 percents of patients with Crohn's disease and 30-40 percents of patients with ulcerative colitis do not respond to these treatments. To date, no comparative study between the two drugs has been carried out and the clinical trials can not be directly compared to each others, still, on the basis of general considerations, there is no essential difference in the effectiveness between the two treatments.
肿瘤坏死因子-α阻断疗法的引入给炎症性肠病的难治性患者治疗带来了巨大变化。英夫利昔单抗和阿达木单抗在中度至重度克罗恩病中均有效。此外，英夫利昔单抗在溃疡性结肠炎的缓解及维持缓解方面效果显著。然而，在难治性患者中，20% - 30%的克罗恩病患者和30% - 40%的溃疡性结肠炎患者对这些治疗无反应。迄今为止，尚未对这两种药物进行比较研究，且各项临床试验之间无法直接进行比较，不过，基于一般考量，这两种治疗方法在有效性方面并无本质差异。
